Structure Therapeutics (GPCR) Competitors $19.30 +0.16 (+0.84%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$18.90 -0.40 (-2.07%) As of 08/29/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. AAPG, KRYS, ACAD, ADMA, TLX, PCVX, PTCT, LNTH, ACLX, and AKROShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), PTC Therapeutics (PTCT), Lantheus (LNTH), Arcellx (ACLX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Vaxcyte PTC Therapeutics Lantheus Arcellx Akero Therapeutics Structure Therapeutics (NASDAQ:GPCR) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do insiders and institutionals have more ownership in GPCR or AAPG? 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is GPCR or AAPG more profitable? Ascentage Pharma Group International's return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% Ascentage Pharma Group International N/A N/A N/A Do analysts recommend GPCR or AAPG? Structure Therapeutics presently has a consensus target price of $75.71, indicating a potential upside of 292.30%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer GPCR or AAPG? In the previous week, Structure Therapeutics had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 7 mentions for Structure Therapeutics and 3 mentions for Ascentage Pharma Group International. Structure Therapeutics' average media sentiment score of 1.47 beat Ascentage Pharma Group International's score of 0.76 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, GPCR or AAPG? Ascentage Pharma Group International has higher revenue and earnings than Structure Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-18.38Ascentage Pharma Group International$134.35M29.39-$55.54MN/AN/A SummaryStructure Therapeutics beats Ascentage Pharma Group International on 6 of the 10 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11B$3.08B$5.71B$9.76BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-18.3820.7883.1026.57Price / SalesN/A393.33544.91112.35Price / CashN/A43.5325.6628.92Price / Book1.289.7811.766.08Net Income-$122.53M-$54.01M$3.27B$265.84M7 Day Performance3.93%0.10%1.13%0.36%1 Month Performance9.72%8.52%8.30%5.58%1 Year Performance-49.38%7.03%62.26%19.67% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.7695 of 5 stars$19.30+0.8%$75.71+292.3%-49.4%$1.11BN/A-18.38136News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600News CoverageGap DownHigh Trading VolumeKRYSKrystal Biotech4.715 of 5 stars$146.77-2.5%$210.38+43.3%-24.3%$4.36B$290.52M29.83210Positive NewsACADACADIA Pharmaceuticals3.7816 of 5 stars$25.32-1.6%$28.88+14.0%+56.8%$4.34B$957.80M19.04510News CoverageAnalyst RevisionADMAADMA Biologics4.274 of 5 stars$17.01-4.4%$27.67+62.6%-0.3%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AAnalyst RevisionGap DownPCVXVaxcyte2.3597 of 5 stars$30.45-5.7%$136.50+348.3%-61.9%$4.19BN/A-7.41160Positive NewsPTCTPTC Therapeutics4.2796 of 5 stars$49.30-2.5%$69.15+40.3%+39.7%$4.02B$806.78M7.071,410Positive NewsLNTHLantheus4.7423 of 5 stars$56.16-3.5%$105.50+87.9%-48.4%$3.96B$1.53B14.94700Positive NewsACLXArcellx1.874 of 5 stars$68.49-3.9%$114.31+66.9%+0.9%$3.95B$107.94M-20.0380News CoveragePositive NewsAKROAkero Therapeutics3.991 of 5 stars$47.03-4.5%$81.57+73.4%+71.8%$3.94BN/A-23.5230Positive News Related Companies and Tools Related Companies Ascentage Pharma Group International Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives ADMA Biologics Alternatives Telix Pharmaceuticals Alternatives Vaxcyte Alternatives PTC Therapeutics Alternatives Lantheus Alternatives Arcellx Alternatives Akero Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts